全球标靶化微脂体药物传递市场规模、份额、成长分析（按微脂体类型、应用、标靶化药物类型）- 产业预测，2024-2031 年

2022年全球标靶化微脂体体给药市场规模为14.8亿美元，从2023年的15.5亿美元成长到2031年的22亿美元，预测期（2024-2031）预计复合年增长率为4.5%。

由于药物递送技术的进步，全球标靶化微脂体药物递送市场正在显着成长。标靶化微脂体提供精确和受控的药物释放，减少副作用并提高治疗效果。慢性病盛行率的上升和对个人化医疗的需求不断增加是推动市场扩张的关键因素。此外，持续的研发、策略合作伙伴关係以及医疗保健领域不断增加的投资正在进一步推动市场成长。北美和欧洲受益于强大的医疗基础设施，而亚太地区由于对医疗进步的兴趣增加和不断增长的患者群体而提供了巨大的商机。值得注意的趋势包括新型製剂的出现和标靶化治疗的探索，凸显了标靶化微脂体药物递送市场的动态和不断发展的性质。

目录

执行摘要

• 市场概况
• 繁荣与衰落

调查方法

• 资讯采购
• 次要和主要资料来源
• 市场规模估算
• 市场假设与限制

母市场分析

• 市场概况
• 市场规模
• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务

主要市场考察

• 技术分析
• 价格分析
• 供应链分析
• 价值链分析
• 市场生态系统
• 智慧财产权分析
• 贸易分析
• Start-Ups分析
• 原料分析
• 创新矩阵
• 研发线产品分析
• 总体经济指标
• 主要投资分析
• 关键成功因素
• 竞争程度

市场动态及前景

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 监管环境
• 波特的分析
• 对未来中断的特殊考虑

全球标靶化微脂体药物递送市场：按微脂体类型

• 市场概况
• 聚乙二醇化微脂体
• 阳离子微脂体
• 阴离子微脂体
• 中性微脂体

全球标靶化微脂体给药市场：依应用分类

• 市场概况
• 癌症治疗
• 感染疾病治疗
• 眼科治疗
• 心血管疾病的治疗
• 其他的

全球标靶化微脂体药物递送市场：按标靶化药物类型

• 市场概况
• 化疗药物
• 抗真菌药物
• 抗生素
• 免疫调节剂
• 其他的

全球标靶化微脂体给药市场规模（按地区）

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2021年）
• 主要市场参与者所采取的策略
• 关键成功策略
• 近期市集活动
• 主要企业市场占有率（2021年）

主要企业简介

• Alnylam Pharmaceuticals
• Acuity Pharmaceuticals, Inc.
• Jubilant Therapeutics
• Verifor Pharmaceuticals
• BIND Therapeutics
• Paladin Labs
• Lipo Therapeutics
• Pharming Group NV
• Johnson & Johnson Services, Inc.
• Gilead Sciences, Inc.
• Sun Pharmaceutical Industries Ltd.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Janssen Pharmaceuticals, Inc.
• CELSION Corporation
• Abbott
• Ipsen Pharma
• Spectrum Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Roche Holding AG

Global Targeted Liposomes Drug Delivery Market size was valued at USD 1.48 billion in 2022 and is poised to grow from USD 1.55 billion in 2023 to USD 2.20 billion by 2031, growing at a CAGR of 4.5% during the forecast period (2024-2031).

The global Targeted Liposomes Drug Delivery Market is witnessing substantial growth driven by advancements in drug delivery technologies. Targeted liposomes offer precise and controlled drug release, diminishing side effects and enhancing therapeutic effectiveness. The rising prevalence of chronic diseases and the increasing demand for personalized medicine are key factors driving market expansion. Moreover, ongoing research and development efforts, strategic partnerships, and heightened investment in healthcare further propel market growth. Leading in market share, North America and Europe benefit from robust healthcare infrastructure, while the Asia-Pacific region presents lucrative opportunities fueled by a growing focus on healthcare advancements and an expanding patient base. Notable trends include the emergence of novel formulations and the exploration of targeted therapies, underscoring the dynamic and evolving nature of the Targeted Liposomes Drug Delivery Market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Targeted Liposomes Drug Delivery Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Targeted Liposomes Drug Delivery Market Segmental Analysis

The global Targeted Liposomes Drug Delivery market is segmented into four major segments i.e. by By Type of Liposomes, Application, Targeted Drug Type, and region. Based on Type, it is divided into PEGylated Liposomes, Cationic Liposomes, Anionic Liposomes, Neutral Liposomes. Based on Application, it is bifurcated as Cancer Therapy, Infectious Disease Treatment, Ophthalmological Treatment, Cardiovascular Disease Treatment, Other Therapeutic Areas. Based on Targeted Drug Type it is segregated into, Chemotherapy Drugs, Antifungal Drugs, Antibiotic Drugs, Immunomodulatory Drugs, Other Drug Types. Based on region, the market is segmented into United States, Canada, and Mexico.

Drivers of the Global Targeted Liposomes Drug Delivery Market

The increasing need for customized and precise pharmaceuticals highlights the significant role of focused liposomes as essential drug delivery agents. These specialized carriers enable precise and controlled release, effectively reducing side effects and enhancing therapeutic effectiveness. With the rising prevalence of chronic conditions, notably cancer, there's a heightened focus on advanced drug delivery methods such as targeted liposomes.

Restraints in the Global Targeted Liposomes Drug Delivery Market

One of the key obstacles in the market revolves around the elevated costs associated with cutting-edge liposomal formulations and technologies, potentially impeding widespread accessibility. Moreover, regulatory intricacies and varying approval processes across different regions compound these challenges, potentially prolonging the introduction of new liposomal products into the market.

Market Trends of the Global Targeted Liposomes Drug Delivery Market

The growing emphasis on personalized medicine is driving the exploration of customized liposomal formulations tailored to individual patient needs. Continuous advancements in liposomal technology, including the creation of intelligent and stimuli-responsive liposomes, underscore the industry's commitment to enhancing drug delivery accuracy, reflecting a concerted effort towards precision medicine.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Targeted Liposomes Drug Delivery Market by Type of Liposomes

• Market Overview
• PEGylated Liposomes
• Cationic Liposomes
• Anionic Liposomes
• and Neutral Liposomes

Global Targeted Liposomes Drug Delivery Market by Application

• Market Overview
• Cancer Therapy
• Infectious Disease Treatment
• Ophthalmological Treatment
• Cardiovascular Disease Treatment
• and Other Therapeutic Areas

Global Targeted Liposomes Drug Delivery Market by Targeted Drug Type

• Market Overview
• Chemotherapy Drugs
• Antifungal Drugs
• Antibiotic Drugs
• Immunomodulatory Drugs
• and Other Drug Types

Global Targeted Liposomes Drug Delivery Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Alnylam Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acuity Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Verifor Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BIND Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Paladin Labs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lipo Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharming Group N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CELSION Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments